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Novel approachAbstract Tuberculosis (TB) is a growing unsolved health concern, as it is the main infectious cause
of death in the globe. The ability of the pathogen to develop into a dormant state is the main obsta-
cle in overcoming the disease. It seems that the development of compounds that can target latent TB
is the key to eradicate this pathogen. In this regard, many researchers started to search for novel
compounds that could inhibit the activity of molecules involved in the resuscitation of latent bacilli.
The discovery of an extremely potent anti-dormancy factor, a resuscitation-promoting factor (Rpf)
from Micrococcus luteus, shifted the idea towards developing potent inhibitors of Rpfs to establish
latent TB and avoid reactivation of the sleeping pathogen. However, besides the advantages of this
approach over the application of annoying long-term regimes of toxic antibiotics, such approaches
that rely on silencing latent TB have many drawbacks that may question their application in human
research. The major drawback of the current approaches is that they hide the latent TB rather than
treating/eradicating it. Here, we propose a novel cost-effective approach that could effectively erad-
icate both active and latent TB in a short period of time without having any risk of reactivation.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Tuberculosis is a growing global health concern
Mycobacterium tuberculosis (MTB) is one of the most success-
ful bacterial parasites of humans, affecting over one-third ofof Medical Biotechnology, Faculty
0.
r (R. Jahanban-Esfahlan).
this study.
niversity of Medical Sciences. Pub
h/
/j.jmhi.2013.04.002the population of the world as a latent infection without clin-
ical symptoms [1]. The number of diagnosed cases reached 8.7
million in 2011 [2,3]. In this context, tuberculosis (TB) ranks as
the leading cause of death from a single infectious agent before
malaria and HIV, and it leads to approximately 2 million
deaths every year [4]. Moreover, studies show that there is aof Advanced Medical Sciences, Tabriz University of Medical Sciences,
lished by Elsevier Ltd.Open access under CC BY-NC-ND license.
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diseases such as lung cancer [5–7]. People who are immuno-
compromised, in particular the HIV cases, have the highest
risk for developing active TB [8–10]. Full eradication of TB
is hampered by the ability of the parasite to survive up to dec-
ades in a dormant state, initially in hypoxic tubercles in the
lung, and to drive recurrent and resistant forms [11]. Dor-
mancy/latency is a reversible physiological state of bacteria
in which cells can remain for a long period of time without
division [12,13]. Dormancy is a viable but non-culturable state
that was ﬁrst detected in Vibrio cholerae in 1982 [14]. Treat-
ment of active TB in humans by a regimen combining four
drugs (isoniazid, rifampicin, pyrazinamide and ethambutol)
leads to rapid killing of the bacteria during the ﬁrst 2 months
[15,16]. However, relapses and multidrug resistance (MDR)
frequently occur if the therapy is not continued further for
4 months to kill the remaining bacilli [17]. A new generation
of antibiotics developed but none gained satisfactory results
in controlling disease [18]. Furthermore, none of the TB vac-
cines studied so far effectively hinders the development of pul-
monary TB in tested animal models [19]. Besides, patient
compliance, cost of drugs and increased frequency of drug-
resistant MTB strains that require application of long-term
toxic dosages of antibiotics have added to the urgent require-
ment for developing novel TB therapies.Forms of TB: latent TB versus active TB
TB has two faces: the active symptomatic form and the dor-
mant (latent) asymptomatic one. Diagnosis of the active form
is easy because patient represents the symptomatic signs of TB
and this form is susceptible to a standard antibiotic regime [1].
The dormant (latent) form is the asymptomatic form in which
the bacilli has a state of non-dividing form and could persist
against antibiotic regimes [16]. About 90% of TB cases devel-
op a latent TB infection. MTB bacteria are captured by white
blood cells in lesions named ‘tubercles’ or ‘granulomas’ [12].
The resident evil inside the tubercle stays in a live, non-cultur-
able state, and the situation leads to a weakened immune re-
sponse, allowing the latent evil to get rid of the lesion and
reactivate into active TB [9]. It is assumed that resistant and
recurrent forms of TB could be eradicated by targeting the
molecules and pathways involved in the dormant state of the
bacilli.Table 1 Comparison between the features of proposed approach w
Method Antibiotic therapy
Features
Require toxic doses +
Kill active bacilli +
Kill dormant bacilli 
Emergence of recurrent TB +
Developing resistant forms +
Capable to eradicate latent TB 
Low doses of drug required 
Safety(no reactivation of disease) 
Easy and fast process for drug development 
Short length of treatment 
Require permanent use of drug +
Cost eﬀective Approaches developed to combat latent TB
Considering the emergence of resistant forms of TB and under-
standing about the relation between the latent form and recur-
rent disease, a large body of papers (most of them consisting of
genome-wide analyses and in silico studies) focussed on devel-
oping compounds that could block the activation of latent ba-
cilli [2,20–32]. In this regard, Dennis J Murphy and James R
Brown performed a meta-analysis of several published data
sets from microarray experiments coupled with genome-wide
insertional mutagenesis that modelled infection leading to a
dormant state. Based on bioinformatic prediction, several
genes including those involved in adenosine triphosphate
(ATP) synthesis, carbon synthesis and enzymes of redox bal-
ance and respiration, sulphur transport and ﬁxation and pan-
tothenate, isoprene and nicotinamide adenine dinucleotide
(NAD) biosynthesis were identiﬁed as gene targets against
the dormant phase of MTB infections [2].
In another study, Vilcheze et al. searched for novel inhibitors
of InhA through the new possible inhibitors of enoyl–acyl car-
rier protein (ACP) reductase and a library of 300 compounds
inhibiting Plasmodium falciparum enoyl reductase. The authors
identiﬁed four compounds that effectively killed TB bacilli un-
der aerobic (active form) and anaerobic (latent form) condi-
tions. Subsequently, in vitro examination of these compounds
shows that only two compounds (CD39 and CD117) were effec-
tive against drug-susceptible and drug-resistant MTB [26].
In another genome-wide-screening-based study, Stanley
et al. screened a whole cell with various libraries of small mol-
ecules as an approach for the detection and introduction of no-
vel inhibitors of MTB. In this way, they found two novel
inhibitors – a benzimidazole and a nitro-triazole – both target
proteins required for cell wall biosynthesis in MTB [33]. In
their study, Stanley et al. added two other inhibitors to the
large list of anti-latent TB compounds.
Rpfs: promising molecules to target latent TB
The view of bacterial dormancy and resuscitation was revolu-
tionised when the role of Rpf from Micrococcus luteus was re-
vealed by Mukamolova et al. in 1998 [34–36]. In M. luteus,
picomolar concentrations of Rpf are needed to revive and resus-
citate the growth of dormant bacilli [18,37,38]. MTB contains
ﬁve Rpf-like genes which products, RpfA–E, promote replica-ith the previous ones.
Inhibitors of latent TB RPFs+ antibiotic therapy
+ 
+ +
 +
+ 
± 
 +
 +
 +
 +
 +
+ 
 +
A novel approach to eradicate latent TB: Based on resuscitation promoting factors 71tion and resuscitation of mycobacterial cells [40]. RpfB, one of
the ﬁveRpfs secreted byTBbacilli, has a crucial role in the resus-
citation and growth stimulation of latent MTB. It is likely that
this domain has biological features and immunogenicity similar
to that of the full-length Rpf [41]. Studies show that RpfB is the
most hopeful candidate of the ﬁve Rpf-like proteins regarding
its immunogenicity and protective efﬁcacy and these features
propose it as a novel subunit vaccine for prevention of TB
[41,42]. Hence, the authors picked out the RpfB domain protein
from MTB to test the proposed hypothesis.
As Rpfs are the extensively potent anti-dormancy factors
known until now [14], the second series of researches focussed
on searching for compounds with potent anti-Rpf activities.
In this way, Galina et al. were the ﬁrst who used a new class
of 2-nitrophenylthiocyanate (NPT) compounds to suppress theFigure 1 Comparison of Current approaches with our proposed app
such condition without administration of anti TB drugs or inhibit
(asymptomatic phase of disease) and active form of bacilli (Symptom
antibiotics can kill all active form of bacilli but fail to eliminate the laten
of dormant bacilli. (B) Current approaches based on silencing latent T
bacilli will be established by using inhibitors of Rpfs or other synthesiz
latent bacilli. This approach requires a permanent dose of inhibitors
proposed approach based on activation of RPFs: This method takes a
RPFs. While activated form of bacilli are susceptible to antibiotics, so
activated bacilli. Consequently this approach is capable to eliminate benzymatic activity of Rpfs in vitro. It was demonstrated that a
synthesised family of NPTs signiﬁcantly inhibited sprouting of
fungal spores and possess similar structures to Rpfs; hence,
they were considered as potent inhibitors of cell wall hydro-
lases and subsequent resuscitation of latent organisms
[43,44]. In this study, Galina et al. introduced NPTs as the ﬁrst
example of low-molecular-weight compounds that exert inhib-
itory effects on the muralytic activities of Rpfs [43]. Recently
characterised NPT compounds could be used as a promising
scaffold for the generation of therapeutic agents to prevent
reactivation of latent TB [39].
In another study, Fan et al. developed monoclonal antibod-
ies against the MTB RpfB domain in mice. They successfully
produced three speciﬁc and effective monoclonal antibodies
(MAbs) against the RpfB domain that suppress the promotingroach for eradication of latent TB. (A) TB without treatment: In
ors of RPF there is repeated periods of latent form of bacilli
atic and acute phase of disease). Administration of standard TB
t ones. So the recurrent form of TB occurs as a result of activation
B by deactivation of Rpfs. In this approach the dormant state of
ed compound against the other factors involved in resuscitation of
and the risk of reactivation of latent TB still remain. (C) Our
dvantage of conversion of dormant bacilli into activated bacilli by
the high serum concentration of anti TB drugs will eliminate newly
oth active and dormant form of TB.
72 K. Seidi, R. Jahanban-Esfahlaneffect of the RpfB domain on the growth of MTB H37Ra
strain and M. luteus, suggesting that MAbs produced against
the RpfB domain might be able to suppress the reactivation
of latent MTB in vivo [41]. In this study, Fan et al. produced
MAbs rather than chemical compounds to inhibit the activity
of Rpfs.
Although the above approaches eliminate using toxic intol-
erable antibiotic regimes, the main concern, which is the acti-
vation of the silent volcano of latent TB and the risk of
reactivation (safety issue), still remains. These approaches
are limited to in vitro/in vivo experiments under laboratory
conditions and because of their safety issue none meet their
clinical trial phase. Furthermore, these approaches are only
applicable in the case of patients with conﬁrmed TB; while
such patients receive immunosuppressive drugs, these condi-
tions put them at serious risk of reactivation of latent TB.
On the other hand, the large number of cases with undiag-
nosed TB will be missed. These limitations push forward the
idea of how to develop an approach that could eradicate latent
TB rather than ignore it; hence, we thought about the optimi-
sation of a reverse approach with the highest beneﬁts for theFigure 2 Different steps required forpatients. The main advantages of the proposed approach over
other approaches are shown in Table 1.
The hypothesis
As discussed before, among the current strategies to avoid
recurrence of TB, all concentrate on neutralising factors that
are responsible for activation of latent TB. In contrast to pre-
vious approaches, which attempt to inhibit activation of Rpfs,
we propose the reverse approach. We emphasise the activation
of dormant bacilli within a deﬁned time after the administra-
tion of a standard antibiotic regime for TB. Activation of Rpfs
will kill all TB repertoires and so will eradicate any recurrence
of TB in the treated subjects and will lower signiﬁcantly the
need for long-term expensive and toxic regimes in resistant
forms. The main idea of our hypothesis is depicted in Fig. 1.
Evaluation of the hypothesis
Several mouse models have been developed for studying latent
TB [45,46]. In this regard, we propose relatively resistantevaluation of proposed hypothesis.
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controls the growth of bacilli and provides a reliable latent
model of TB [18,45]. As reviewed in reference 46, it takes
approximately 1 month to develop a latent mouse model of
TB. After this step, 20 latent TB mouse models will be divided
in two equal groups as the control and experimental groups.
Both groups will receive the same dose and regime of antibiot-
ics (e.g., isoniazid, rifampicin, pyrazinamide and ethambutol).
After 1 month when the serum level of antibiotics would reach
the maximum concentration, the experimental group will re-
ceive a single dose of picomolar concentrations of RpfB do-
main protein through an inhalation chamber while at the
same time the antibiotic therapy will be continued for both
groups for another 2 weeks to ensure the stable high serum le-
vel of antibiotics. After 2 weeks, both control and experimen-
tal mice will be scariﬁed and their lungs will be cultured to
identify MTB bacilli. According to our hypothesis, it is pre-
dicted that control mice that received only antibiotics will be
positive for the presence of TB bacilli. However, in experimen-
tal mice we expect a negative result because all dormant bacilli
are activated by administration of Rpf and subsequently killed
by exposure to high level of antibiotics; hence, the lung culture
of treated mice should be TB negative. By this simple method
that requires simple techniques such as pathology, one could
easily evaluate the efﬁcacy of proposed approach (Fig. 2).Discussion and conclusion
TB still is a serious concern to human health affecting a large
number of people throughout the world. In contrast to the
accessible drugs applied for the treatment of TB, the long che-
motherapeutic regimens frequently contribute towards the
resistant and recurrent forms and this even requires toxic doses
which are not tolerable by the patients [1–5]. Latency is a cru-
cial characteristic of TB that enables the bacilli to survive in
granulomatous lesions for decades and cause MDR and recur-
rent TB [9–12]. Therefore, strategies emerged to target and
deactivate the latent form by developing various compounds
against factors which are responsible for the latent state of
the bacilli as discussed earlier [22–31]. Although these ap-
proaches seem to be a better choice over those cases which
are resistant to standard antibiotic regimes, they have major
drawbacks too. They were all conducted only under in vitro/
in vivo conditions and they have not met animal or clinical trial
studies. They do not cure latent TB but they just hide the exis-
tence of a latent TB. Considering Rpfs as the major factors
responsible for resuscitation of dormant bacilli, the idea of
using this protein as a potent tool against the pathogen itself
emerged. Our proposed approach and the simple proposed
protocol to test it in an animal model could easily and
promptly undergo its clinical trial phase in a human popula-
tion; and instead of an inhalation chamber, one could easily re-
ceive Rpfs through an aerosol inspiration similar to that of an
asthma patient. The only concern about this approach is the
time of administration of Rpf that will convert all latent bacilli
into activated forms; but this concern is already solved by the
presence of high serum level of antibiotics that are ready to
clear host body of any activated antibiotic-susceptible bacilli.
The proposed approach is simple, easy, fast, safe and cost-
effective and as it can target the latent TB it leaves no chance
for the reactivation of latent TB.Conﬂict of interest statement
None declared.Overview Box
What do we already know about the subject?
TB is one of the most prevalent infectious diseases
worldwide. The major obstacle for full eradication of
TB attributed to the dormant state of the bacilli. Rou-
tine combinatorial antibiotic therapy is only applicable
to the active form of the disease, while dormant forms
persist and provide the recurrent or resistant form of
the disease.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
All approaches focus on strategies that prevent the
activation of dormant bacilli. This approach could
not guarantee the full control of disease and at any
time the dormant forms have a chance to reactivate.
We propose the reverse approach that seems to be a
more reliable strategy. According to our proposed
strategy, by implementation of the active form of Rpfs
and concomitant administration of antibiotics one can
gain the best results – elimination of resistant TB.
Among numerous available studies, what special further
study is proposed for testing the idea?
This approach is a novel idea and there is a simple pro-
tocol to test its feasibility. After predicted results
obtained in animal models, the human clinical trial
studies can be implemented too.References
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